Evidence map›Paper›PMID 37240924›Full record

ReviewJournal of personalized medicine2023

An Update on Tamoxifen and the Chemo-Preventive Potential of Vitamin E in Breast Cancer Management.

Farid Khallouki, Lhoussain Hajji, Somayya Saber, Toufik Bouddine, Mouad Edderkaoui, Mohammed Bourhia, Nora Mir, Adrian Lim, Adil El Midaoui, John P Giesy and 3 more

Open access · goldAbstract readReview
In one paragraph

Review in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 5 countries.

Farid KhalloukiBiology Department, FSTE, Moulay Ismail University of Meknes, BP 609, Errachidia 52000, Morocco.
Lhoussain HajjiBiology Department, Faculty of Sciences, Moulay Ismail University of Meknes, BP. 11201 Zitoune, Meknes 50050, Morocco.
Somayya SaberBiology Department, FSTE, Moulay Ismail University of Meknes, BP 609, Errachidia 52000, Morocco.
Toufik BouddineBiology Department, Faculty of Sciences, Moulay Ismail University of Meknes, BP. 11201 Zitoune, Meknes 50050, Morocco.ORCID 0000-0002-0915-1257
Mouad EdderkaouiDepartments of Medicine and Biomedical Sciences, Cedars-Sinai Medical Center & University of California, Los Angeles, CA 90048, USA.ORCID 0000-0002-2549-8242
Mohammed BourhiaHigher Institute of Nursing Professions and Technical Health, Laayoune 70000, Morocco.ORCID 0000-0003-3707-8461
Nora MirBiology Department, Faculty of Sciences, Moulay Ismail University of Meknes, BP. 11201 Zitoune, Meknes 50050, Morocco.
Adrian LimDepartments of Medicine and Biomedical Sciences, Cedars-Sinai Medical Center & University of California, Los Angeles, CA 90048, USA.ORCID 0000-0002-4638-9395
Adil El MidaouiBiology Department, FSTE, Moulay Ismail University of Meknes, BP 609, Errachidia 52000, Morocco.
John P GiesyToxicology Centre, University of Saskatchewan, Saskatoon, SK S7N 5B3, Canada.ORCID 0000-0003-1931-9962
Mourad A M Aboul-SoudMedical and Molecular Genetics Research, Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh 11433, Saudi Arabia.ORCID 0000-0001-9395-0563
Sandrine Silvente-PoirotCancer Research Center of Toulouse, UMR 1037 INSERM, UMR 5071 CNRS, University of Toulouse III, Equipe labellisée par la Ligue Nationale Contre le Cancer, 31037 Toulouse, France.
Marc PoirotCancer Research Center of Toulouse, UMR 1037 INSERM, UMR 5071 CNRS, University of Toulouse III, Equipe labellisée par la Ligue Nationale Contre le Cancer, 31037 Toulouse, France.ORCID 0000-0002-5711-6624
Université Moulay Ismail de Meknes · MACedars-Sinai Medical Center · USCentre National de la Recherche Scientifique · FRBaylor University · USInstituts Supérieurs des Professions Infirmières et Techniques de Santé · MAKing Saud University · SA

Funding

University of Toulouse-Jean Jaurès internal grant from the "Institut National de la Santé et de la Recherche Médicale", the "Universi-té de Toulouse III", the Institut National contre le Cancer (INCA) (PRTK-K15-118, PLBIO-2018-145) and the association "Elles
6 · The paper itself

Abstract

Breast cancer (BC) is the most common female cancer in terms of incidence and mortality worldwide. Tamoxifen (Nolvadex) is a widely prescribed, oral anti-estrogen drug for the hormonal treatment of estrogen-receptor-positive BC, which represents 70% of all BC subtypes. This review assesses the current knowledge on the molecular pharmacology of tamoxifen in terms of its anticancer and chemo-preventive actions. Due to the importance of vitamin E compounds, which are widely taken as a supplementary dietary component, the review focuses only on the potential importance of vitamin E in BC chemo-prevention. The chemo-preventive and onco-protective effects of tamoxifen combined with the potential effects of vitamin E can alter the anticancer actions of tamoxifen. Therefore, methods involving an individually designed, nutritional intervention for patients with BC warrant further consideration. These data are of great importance for tamoxifen chemo-prevention strategies in future epidemiological studies.

Indexed as

AEBSautophagybreast cancerChEHcholesterol biosynthesischolesterol metabolismcytotoxicityestrogen receptoroxytserolsresistancetamoxifen

Identifiers

PMID37240924
PMCPMC10221210
OpenAlexW4367299460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.